MLTX INVESTOR ALERT: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) on behalf of investors who experienced substantial losses. The lawsuit alleges that MoonLake and its executives violated the Securities Exchange Act of 1934 by making false and/or misleading statements regarding their drug candidate, sonelokimab (SLK). Specifically, the complaint claims that SLK, intended for the treatment of hidradenitis suppurativa (HS), was falsely presented as having a superior clinical benefit over BIMZELX, a competitor drug. The lawsuit asserts that SLK’s Nanobody structure would not provide a clinical advantage and that its tissue penetration would not translate to efficacy. Following the announcement of Phase 3 trial results on September 28, 2025, which showed SLK failed to demonstrate competitive efficacy, MoonLake’s stock price plummeted nearly 90%. Investors who purchased MoonLake common stock during the class period are eligible to seek appointment as lead plaintiff by December 15, 2025. Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024.

(Source：GuruFocus)